In muscle, FoxO1 activation by ROS downregulates glucose transporter type 4 (GLUT4) and induces atrophy programs (Atrogin-1/MuRF1), impairing glucose uptake and promoting sarcopenia [54, 55]. Here, FBXO32 is linked to sarcopenia.